You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Johnson and Johnson
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLIPIZIDE; METFORMIN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Glipizide; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00513630 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed Shanghai Jiao Tong University School of Medicine Phase 4 2004-06-01 The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation
NCT00648505 Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg Completed Mylan Pharmaceuticals Phase 1 2005-06-01 The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fed conditions.
NCT00649454 Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg Completed Mylan Pharmaceuticals Phase 1 2005-06-01 The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting conditions.
NCT00660907 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed Bristol-Myers Squibb Phase 3 2008-03-01 This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
NCT00660907 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed AstraZeneca Phase 3 2008-03-01 This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glipizide; Metformin Hydrochloride

Condition Name

Condition Name for Glipizide; Metformin Hydrochloride
Intervention Trials
Healthy 4
Type 2 Diabetes 2
Type 2 Diabetes Mellitus 2
Coronary Artery Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Glipizide; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus 7
Diabetes Mellitus, Type 2 6
Coronary Disease 1
Hyperglycemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Glipizide; Metformin Hydrochloride

Trials by Country

Trials by Country for Glipizide; Metformin Hydrochloride
Location Trials
United States 42
Hungary 8
Israel 8
India 7
Mexico 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Glipizide; Metformin Hydrochloride
Location Trials
North Dakota 5
Minnesota 2
Massachusetts 2
Illinois 2
New Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Glipizide; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Glipizide; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Glipizide; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 8
Unknown status 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Glipizide; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Glipizide; Metformin Hydrochloride
Sponsor Trials
Bristol-Myers Squibb 2
Mylan Pharmaceuticals 2
Teva Pharmaceuticals USA 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Glipizide; Metformin Hydrochloride
Sponsor Trials
Industry 9
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Baxter
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.